4DMedical Expands with New Contracts & US Recognition

About 4DMedical Limited

4DMedical Limited (ASX: 4DX), founded in 2013 and headquartered in Melbourne, is a medical technology company developing advanced imaging software for respiratory diagnostics. Its flagship XV Technology uses AI and proprietary algorithms to create four-dimensional views of lung function from standard CT and X-ray images. The company delivers its platform as a scalable SaaS solution used in both clinical and research settings. 4DMedical is currently trading at $0.27 per share.

Clinical Trial Partnerships Strengthen Commercial Pipeline

4DMedical has entered two commercial agreements to apply its lung imaging technology in clinical research. The first is with SMS Biotech, a US-based biotechnology company developing a novel stem cell treatment for chronic obstructive pulmonary disease (COPD). The imaging platform will be used to assess lung function before and after treatment in trial participants. The initial scope includes 42 scans, valued at US$40,000, with the potential to scale across a larger patient cohort and international trial sites.

The second contract is with a leading multinational medical device developer. While details remain confidential, the agreement involves using 4DMedical’s technology in the evaluation and monitoring of a new implantable device for respiratory patients. Both agreements reflect growing demand from the life sciences sector for precision imaging tools to support clinical development, patient monitoring, and regulatory validation.

These new contracts also add to 4DMedical’s expanding list of research collaborations, reinforcing its value proposition as a preferred imaging partner in pharmaceutical and medical device innovation.

Recognised in US Healthcare Policy Discussions

4DMedical’s lung imaging software was also referenced in recent testimony to the US House Committee on Veterans’ Affairs, which is reviewing healthcare modernisation strategies for veterans. During the session, the company’s technology was highlighted as a tool capable of delivering faster, more accurate diagnoses for respiratory conditions, particularly for veterans exposed to deployment-related toxins.

The imaging platform, already integrated into major equipment vendor systems, was identified as helping reduce diagnostic delays and improving care outcomes across the Veterans Affairs (VA) health network. Its ability to detect functional abnormalities earlier and more accurately than traditional methods was noted as a key advantage for both patients and healthcare systems.

The platform’s deployment within the VA system could support thousands of facilities nationwide, potentially streamlining respiratory diagnostics and reducing the overall burden of lung disease within the veteran population.

Delivering Scalable Respiratory Imaging Solutions

4DMedical’s Lung Ventilation Analysis Software (LVAS®) uses non-invasive methods to generate highly detailed maps of airflow throughout the lungs. This capability allows clinicians to identify early signs of disease and track treatment response with greater accuracy. The technology is applicable across a range of respiratory conditions including asthma, COPD, interstitial lung disease (ILD), and pulmonary fibrosis.

Delivered via a cloud-based SaaS model, the software can be rapidly integrated into existing hospital infrastructure, eliminating the need for specialised hardware. This flexibility has made it increasingly attractive to health systems seeking scalable and cost-effective solutions to improve respiratory care.

Recent enhancements to the company’s product suite, including the integration of artificial intelligence through the acquisition of US-based firm Imbio, further strengthen its diagnostic capabilities and support wider adoption in both clinical and research settings.

Outlook and Commercial Growth

The latest industry contracts and policy recognition position 4DMedical to expand its commercial footprint across both government and private healthcare channels. The company continues to pursue opportunities in large-scale healthcare systems, life sciences partnerships, and regulatory-driven programs that prioritise early and accurate diagnosis of respiratory diseases.

With a strong technology foundation, growing customer base, and international credibility, 4DMedical remains on track to deliver its respiratory imaging platform to a global audience. The continued execution of its commercial strategy, combined with increasing demand for precision healthcare tools, supports a positive outlook for the company’s long-term growth.